Cellares Raises $277M Series D With ARK Invest

Cellares has successfully closed a substantial $277 million Series D funding round, with notable participation from ARK Invest, which contributed $20 million. This significant capital infusion underscores growing investor confidence in the company's mission to revolutionize cell therapy manufacturing. The round saw broad support from a distinguished list of institutional investors, including BlackRock, Eclipse, T. Rowe Price Investment Management, Baillie Gifford, Duquesne Family Office, Intuitive Ventures, EDBI, Gates Frontier, DC Global Ventures, DFJ Growth, and Willett Advisors.

The financing propels Cellares' efforts to industrialize the production of complex cell therapies through its Integrated Development and Manufacturing Organization (IDMO) framework. This strategic funding arrives as the company achieves critical operational milestones. Recently, Cellares manufactured and delivered its inaugural Good Manufacturing Practice (GMP) cell therapy doses to patients utilizing its proprietary Cell Shuttle platform. Furthermore, the company has secured long-term commercial supply agreements with leading biopharmaceutical entities, signaling a transition from development to commercial readiness.

The cell therapy sector, while scientifically validated, has long grappled with the immense challenge of scaling manufacturing efficiently and cost-effectively. ARK Invest, through its founder and CIO Cathie Wood, identified this bottleneck as the primary hurdle. Cellares' approach, integrating advanced robotics, sophisticated software, and biotechnology, aims to industrialize cell therapy production. This aligns perfectly with ARK Invest's focus on disruptive innovation, as highlighted by Ovid Amadi, Ph.D., Multiomics Portfolio Manager and Director of Research at ARK Invest. He emphasized Cellares' vertically integrated IDMO model, which has demonstrated both technical and commercial viability across numerous manufacturing processes and partnerships.

Evidence of Cellares' market traction includes its role in producing investigational CAR T cell therapy doses for Cabaletta Bio. The company successfully manufactured and delivered the first two GMP doses of rese-cel, which met all release specifications and were administered to patients on schedule. This achievement was swiftly followed by a 10-year commercial supply agreement between Cabaletta Bio and Cellares. These developments build upon Cellares' prior announcement of a significant $380 million global manufacturing pact with Bristol Myers Squibb, reserving commercial-scale capacity across its facilities in the United States, Europe, and Japan for the pharmaceutical giant's cell therapy pipeline.

Cellares is actively expanding its global manufacturing footprint, with existing IDMO Smart Factories in South San Francisco, California, and Bridgewater, New Jersey. New facilities are under development in Leiden, Netherlands, and Kashiwa City, Japan. The company projects its international network will support commercial-scale production for hundreds of thousands of patients annually by 2027. At the core of its innovation are two automated platforms: Cell Shuttle for end-to-end manufacturing and Cell Q for automated quality control. Cellares claims its technology can yield up to ten times more cell therapy batches than traditional contract development and manufacturing organizations (CDMOs), while simultaneously reducing costs and enhancing process consistency.

The Cell Shuttle platform has garnered significant regulatory recognition, becoming the first cell therapy manufacturing system to receive the FDA’s Advanced Manufacturing Technology designation. With a reported 100% automation success rate across more than a dozen manufacturing processes, Cellares has firmly established itself as a clinically validated manufacturing infrastructure provider, moving beyond its initial role as a technology developer. This funding round positions the company to further scale its operations and solidify its leadership in addressing the critical manufacturing challenges within the rapidly advancing cell therapy field.